For Private Equity
Clinical, manufacturing, and regulatory risk assessment validated against documented outcomes — before write-downs happen.
Why We're Different
Traditional due diligence uses financial analysts and generalist consultants who can't evaluate clinical adoption risk (will physicians change workflow?), manufacturing scalability (will it survive production scale-up?), or regulatory pathway viability (is the predicate strategy survivable?). These risks are invisible in financial models.
This isn't a second opinion. It's the first clinical-technical opinion in your deal process.
No equity positions. No outcome-based fees. Engagement-level NDA with zero cross-client data sharing. All material conflicts disclosed in writing.
Your Vantage assessment stands independently — uninfluenced by portfolio incentives or other client interests. This is how we maintain the rigor that matters.
What We Find
Patterns from 12+ years of documented healthcare PE outcomes
Clinical adoption was primary risk
Single-source supplier risk
Write-down rate (unvalidated reimbursement)
Framework accuracy vs. outcomes
Physicians won't change workflow for marginal improvements. We assess adoption barriers that financial DD structurally can't see.
Single-source supplier dependencies, scale-up challenges, and design-for-manufacturing gaps remain invisible until production stress.
Predicate strategies that won't survive FDA scrutiny. Typical remediation: 12-18 months and $1-3M in clinical data.
Devices with unclear payer pathways fail commercially post-FDA clearance. We map coverage sustainability and pricing viability.
Cross-category pattern intelligence with 96% historical accuracy†4. Risks that existing advisors structurally can't see.
Existential risk from single-payer reliance. We model financial impact of coverage changes and rate adjustments.
Your financial, legal, and market advisors handle their domains. These are the clinical-technical risk areas they structurally can't evaluate.
Physician workflow barriers, adoption probability, clinical evidence gaps
Supply chain risk, scale-up readiness, DFM gaps, single-source dependencies
Predicate strategy viability, pathway risk, FDA submission readiness
Payer coverage probability, CPT pathway, ASP sustainability, coding risk
Our Services
Purpose-built for platform and bolt-on acquisition timelines.
Most PE firms start with Bolt-On DD for active deals or Portfolio Triage for existing holdings. All programs include optional Vantage Secure for air-gapped processing with encrypted USB transfer and chain-of-custody documentation.
Vantage doesn't replace your financial, legal, or market DD firms. We add the clinical-technical layer they structurally can't provide — physician adoption analysis, manufacturing scalability assessment, and regulatory pathway validation. Your existing advisors keep doing what they do well. We cover the gap that causes post-close surprises.
Proprietary Assessment
Proprietary assessment covering clinical adoption, manufacturing, regulatory, IP, and team evaluation. IC-ready report with invest/pass recommendation.
Integration-focused assessment
Integration-focused assessment evaluating technology fit, manufacturing compatibility, and clinical synergies with your portfolio.
$18,000–$25,000 per company
Standardized risk scoring across your portfolio for apples-to-apples comparison and resource prioritization.
Dedicated capacity
Dedicated capacity with up to 6 assessments annually, quarterly reviews, priority scheduling, and direct team access.
IC-ready deliverables designed for PE investment committees.
Practicing physician and Medical Director at Adventist Health White Memorial. Chairs P&T Committee evaluating device adoption for 150+ physicians. Brings the clinical adoption perspective that financial DD structurally can't provide.
BS Biomedical Engineering, UC Irvine; MSE Quality, Reliability & Statistical Engineering, ASU. Part of the Axonics operations engineering team that navigated the regulatory and manufacturing path leading to Boston Scientific's $4.1B acquisition.
Identifying clinical and manufacturing risks before close costs a fraction of post-close remediation.
Typical remediation cost when clinical, manufacturing, or regulatory risks emerge post-acquisition
Pre-close assessment identifies the same risks, giving you leverage to adjust terms or walk away
Risk-adjusted ROI when material clinical or manufacturing risks are identified pre-close
Example: A single-source supplier dependency on a critical BOM component, identified pre-close, allows negotiating a $500K dual-sourcing contingency into deal terms. The same risk discovered 12 months post-close during a supply disruption typically requires $3–5M in emergency qualification, production line redesign, and lost revenue.
When Risks Are Discovered
The timing of risk discovery directly impacts deal value.
Sample Deliverable
A preview of the structured intelligence your investment committee receives.
Report ownership: Your Vantage assessment is yours to use in IC memos, LP updates, board materials, and co-investor data rooms. No licensing fees.
Post-Close Value
Your Vantage assessment becomes the foundation for post-acquisition value creation.
PE Deal Workflow
Risk intelligence at every stage — from sourcing through post-close monitoring.
Portfolio screening to identify clinical and manufacturing risks early
Rapid risk triage on target profile and strategic fit
Full assessment with IC-ready report and management questions
Board-ready presentation with risk quantification and recommendations
Integration checkpoints and portfolio risk tracking at 90 days and beyond
From Our Research
Strategies and frameworks for platform and bolt-on acquisition success.
How the PE investment thesis shapes what clinical and manufacturing risks need pre-close validation.
ReadFrom close to 100 days: milestone framework for de-risking acquisition integration and accelerating value creation.
ReadWhy standard manufacturing assessment misses the risks that destroy IRRs post-acquisition.
ReadAnalysis and perspectives for PE healthcare investors
How manufacturing integration risk often derails post-acquisition value realization.
Read article →Why the most common regulatory shortcut in medtech often creates more risk than it eliminates.
Read article →Critical payment pathway risks that traditional due diligence consistently misses.
Read article →Citations: †1 Based on internal analysis of 12 platform DD assessments completed 2020-2025. †2 Internal analysis of acquisition targets showing single-source supplier concentration on critical BOM components. †3 Return differential analysis from documented PE healthcare exits (2015-2024) comparing structured clinical/regulatory/manufacturing DD vs. financial/legal DD only. †4 Retrospective framework accuracy rate validated against documented medical device outcomes across 100+ companies (post-market surveillance data, regulatory submissions, clinical literature). †5 Industry-wide figure: Proximo Medical; MDDI Online compilation. †6 Harvard Business Review (Roger L. Martin, 2016); McKinsey & Company analysis of 2,500+ M&A transactions.
Schedule a discovery call to discuss your portfolio strategy.
Schedule a Discovery CallIn 20 minutes, we'll identify the 3 biggest PE-specific risks for your target — no charge, no obligation.